Comparison
Two repair-associated peptides with very different evidence shapes: one systemic and preclinical, one topical and modestly human.
BPC-157 has strong rodent repair data and thin human data; GHK-Cu has a modest human cosmetic literature for topical use and little behind injectable systemic claims. The right comparison is route-by-route.
For skin, GHK-Cu has the stronger human story: small cosmetic and wound-adjacent studies of topical products. For soft-tissue and gut repair claims, neither has controlled human trials: BPC-157's support is rodent literature plus a few early human reports.
Topical GHK-Cu is a normal cosmetic ingredient; injectable GHK-Cu is a separate, unverified practice. BPC-157 is discussed orally for gut claims and by injection for recovery, with no established human dose for either.
BPC-157 is on FDA's 2026 compounding advisory agenda and flagged in safety-risk materials. GHK-Cu occupies a quieter space as a cosmetic ingredient, though injectable forms sit in the same gray market as everything else.
| Dimension | BPC-157 | GHK-Cu |
|---|---|---|
| Overall evidence grade | D | C |
| Evidence label | Limited human evidence | Moderate human evidence |
| Regulatory status | Not FDA-approved for listed uses | Varies by product and jurisdiction |
| Editorial confidence | Low confidence | Moderate confidence |
| Efficacy | 1/5 limited | 3/5 emerging |
| Safety | 1/5 limited | 2/5 limited |
| Regulatory risk | 4/5 high | 2/5 low |
| Product quality risk | 4/5 high | 3/5 moderate |
| Primary claim categories | Injury recovery, Tendon and ligament claims, Gut and inflammation claims | Skin appearance, Wound-healing research, Hair and cosmetic claims |
BPC-157 has limited human evidence. The most useful sources are an oral trial registry, small human reports, review context, and FDA compounding concerns; the recovery protocol culture is much louder than the human data.
GHK-Cu is strongest for route- and formulation-specific topical dermatology claims. Topical wound and skin sources do not imply injectable or systemic benefits.
PubMed. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing 2025.
PMID:40789979 Accessed 2026-06-08.
Narrative review that helps explain the recovery discussion but does not prove broad clinical recovery efficacy.
ClinicalTrials.gov. ClinicalTrials.gov record NCT02637284 2015.
NCT02637284 Accessed 2026-06-08.
Trial record tracked for BPC-157 evidence mapping; no posted results were used for efficacy conclusions.
PubMed. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper 1994.
PMID:17147644 Accessed 2026-06-08.
Topical diabetic-ulcer source; not evidence for injectable or systemic claims.
PMID:25384620 Accessed 2026-06-08.
Dermal-delivery formulation context; not systemic efficacy evidence.